SEC (Securities and Exchange Commission) considers new rules on analyst information:
This article was originally published in Clinica
The US Securities and Exchange Commission (SEC) is considering a rule change to clarify the information a company can release to selected analysts. After recent dramatic stock price moves and a delayed IPO following so-called "whisper estimates", the Wall Street Journal reports that the SEC's enforcement division has plans to tighten up on private analyst briefings.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.